



Atty. Docket No.: 9409/2045B PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Wittamer, et al.	Examiner:	Not Yet Assigned
Serial No.:	10/603,566	Group Art Unit:	Not Yet Assigned
Filed:	June 25, 2003	Conf. No.:	Not Yet Assigned
Entitled:	"Compositions and Methods Comprising a Ligand of ChemerinR"		

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathleen M. Williams

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449;
3. Copies of Cited References; and
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 9409/2045B. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: October 1, 2003


Name: Kathleen M. Williams

Registration No.: 34,380

Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100



Atty. Docket No.: 9409/2045B

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Wittamer, et al.	Examiner:	Not Yet Assigned
Serial No.:	10/603,566	Group Art Unit:	Not Yet Assigned
Filed:	June 25, 2003	Conf. No.:	Not Yet Assigned
Entitled:	"Compositions and Methods Comprising a Ligand of ChemerinR"		

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathleen M. Williams

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:


In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office. A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list. Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.


Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,

Date: October 1, 2003


Name: Kathleen M. Williams
Registration No.: 34,380
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100


 SPTO Form 1
 U.S. Department of Commerce
 Patent and Trademark Office

Attorney Docket No.

9409/2045B

Serial No.

10/603,566

INFORMATION DISCLOSURE STATEMENT

Applicant(s): Wittamer, et al.

Filing Date: June 25, 2003

Group: Not Yet
Assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Publication Date	Country	Class	Subclass	Translation	
						YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

1.	Adams, et al., "1,25 Dihydroxyvitamin D3 and Dexamethasone Induce the Cyclooxygenase 1 Gene in Osteoclast-Supporting Stromal Cells", (1999), <i>J. of Cellular Biochemistry</i> , 74: 587-595.
2.	Nagpal, et al., "Tazarotene-induced Gene 2 (TIG2), a Novel Retinoid-Responsive Gene in Skin", (1997), <i>J. Invest. Dermatol.</i> , 109: 91-95.
3.	Samson, et al., "ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains", (1998), <i>Eur. J. Immunology</i> , 28: 1689-1700.
4.	Methner, et al., "A Novel G Protein-Coupled Receptor with Homology to Neuropeptide and Chemoattractant Receptors Expressed during Bone Development", (1997), <i>Biochemical and Biophysical Research Communications</i> , 233: 336-342.
5.	Kotani, M., M. Detheux, A. Vandengogaerde, D. Communi, J.M. Vanderwinden, E. Le Poul, S. Brezillon, R. Tyldesley, N. Suarez-Huerta, F. Vandeput, C. Banpain, S.N. Schiffmann, G. Vassart, and M. Parmentier, "The metastasis-suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54", (2001), <i>J.Biol.Chem.</i> 276:34631-34636.
6.	Joost, P., and A. Methner, "Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands", (2002), <i>Genome Biology</i> 3, 0063.1-0063.16.
7.	Lee, D.K., S.R. George, J.F. Evans, K.R. Lynch, and B.F. O'Dowd, "Orphan G protein-coupled receptors in the CNS", (2001), <i>Curr. Opin. Pharmacol.</i> 1:31-39.
8.	Im, D.S., "Orphan G protein-coupled receptors and beyond", (2002), <i>Jpn. J. Pharmacol.</i> 90:101-106.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.